New combo tackles melanoma that outsmarted standard drugs
NCT ID NCT04903119
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 26 times
Summary
This early-phase study tests adding nilotinib to standard targeted therapy for people with advanced melanoma that has a BRAF V600 mutation and has stopped responding to previous BRAF/MEK inhibitor treatment. About 30 participants will receive the drug combination to find the safest dose and understand side effects. The goal is to see if this new mix can control the cancer again.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Markey Cancer Center
RECRUITINGLexington, Kentucky, 40536, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
St. Luke's University Health Network
RECRUITINGEaston, Pennsylvania, 18045, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Iowa
NOT_YET_RECRUITINGIowa City, Iowa, 52242, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Vanderbilt-Ingram Cancer Center
RECRUITINGNashville, Tennessee, 37232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.